Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/14/20
What Makes Adaptimmune Therapeutics PLC (ADAP) a New Strong Buy StockZacks Investment Research • 04/28/20
Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal ProductsGlobeNewsWire • 04/28/20
Why Adaptimmune Therapeutics, Atreca, and CRISPR Therapeutics All Tanked In MarchThe Motley Fool • 04/06/20
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/27/20
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary SharesGlobeNewsWire • 02/07/20
Has Adaptimmune Therapeutics (ADAP) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 02/05/20
Adaptimmune's Data In Treating Solid Tumors Reinforces Prior Data And Highlights Technology PlatformSeeking Alpha • 01/27/20
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary SharesGlobeNewsWire • 01/24/20
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary SharesGlobeNewsWire • 01/22/20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary SharesGlobeNewsWire • 01/21/20
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell TherapiesGlobeNewsWire • 01/14/20
Adaptimmune Soars 250% On Positive Initial Responses For T-Cell Platform In 4 Tumor TypesBenzinga • 01/13/20